Evidence map›Paper›PMID 36211462›Full record

ArticleFrontiers in cell and developmental biology2022

Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer.

Lin Wang, Xiang-Bo Ji, Li-Hong Wang, Jian-Ge Qiu, Feng-Mei Zhou, Wen-Jing Liu, Di-di Wan, Marie Chai-Mi Lin, Ling-Zhi Liu, Jian-Ying Zhang and 1 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Lin WangThe First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Xiang-Bo JiBGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Li-Hong WangBGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Jian-Ge QiuThe First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Feng-Mei ZhouThe First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Wen-Jing LiuDepartment of Oncology, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, China.
Di-di WanBGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Marie Chai-Mi LinThe First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Ling-Zhi LiuDepartment of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, United States.
Jian-Ying ZhangBGI College & Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Bing-Hua JiangThe First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CNZhengzhou University · CNHenan Cancer Hospital · CNThomas Jefferson University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fcell.2020.00840.].

Indexed as

Akt2chemoresistanceMiR-497NSCLCtumor growth

Identifiers

PMID36211462
PMCPMC9542641
OpenAlexW4296846559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.